Doseology Sciences Enhances Transparency Through AIF Filing to Consolidate Disclosure for Investors

Doseology Sciences Enhances Investor Transparency with Annual Information Form Filing

Introduction
In a significant move, Doseology Sciences Inc., a pivotal player in the biotechnology-driven consumer products industry, has officially filed its Annual Information Form (AIF) for the fiscal year ended June 30, 2025. This filing comes as a part of their ongoing commitment to improving communication and governance practices with shareholders, reflecting their dedication to transparency and investor confidence.

Why the AIF Matters
The Annual Information Form is a key document for public companies in Canada, consolidating essential information that is usually spread across numerous disclosures. With this AIF, Doseology aims to provide investors and stakeholders with a more accessible and structured overview of the company's operations, strategies, risk factors, governance practices, and capital structure.

Chris Jackson, the CEO of Doseology, emphasized that, "High-quality disclosure is not just a regulatory requirement — it is a critical part of how we build trust with shareholders over time." This highlights the company’s focus not only on compliance but also on fostering robust relationships with its investors.

Consolidation of Information
By consolidating information into a single document, Doseology enhances the usability of its disclosures for the investment community. Previously, stakeholders might have struggled to piece together necessary information from various reports, leading to potential misunderstandings about the company's positioning and strategies. Now, the AIF simplifies this by providing an all-in-one reference, which is particularly vital as the company has evolved — including its first acquisition and platform development.

Governance Discipline
Maintaining an updated AIF is considered a best practice within corporate governance. This reflects Doseology's commitment to operational transparency and regulatory compliance. While the company routinely assesses strategic and operational opportunities, it's essential to note that the AIF filing does not imply any open or pending financing actions. Any decisions regarding public offerings or financing activities will be guided by the prevailing market conditions and the strategic direction of the company plus regulatory guidelines.

Strategic Timing
Doseology chose to file the AIF now as a response to its changing operational profile, marking a suitable moment to provide a consolidated disclosure to the investment community. This decision underscores the company’s intent to present a clear and structured depiction of its risk landscape and governance practices, without linking this move directly to any immediate financing transaction.

Availability of AIF
The AIF, along with other continuous disclosure documents, can be accessed through Doseology's profile on SEDAR+. This ensures that investors can remain informed about the company’s operations and strategic directions.

About Doseology Sciences Inc.
Doseology operates within the oral stimulant sector, carving out a niche with its innovative approach towards transforming consumer access to energy and nutraceutical products. The company's strategic focus is on product innovation, building intellectual property, and executing disciplined commercial strategies, ensuring sustainable growth through both internal initiatives and selective acquisitions.

Conclusion
With the filing of its AIF, Doseology Sciences Inc. not only meets regulatory obligations but also reinforces its commitment to transparency and effective communication with its shareholders. This strategic move reflects a mature approach to corporate governance and effective stakeholder engagement in a rapidly evolving market landscape.